Replimune (REPL) Operating Income (2017 - 2026)

Replimune (REPL) has 10 years of Operating Income data on file, last reported at -$73.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income rose 7.55% year-over-year to -$73.3 million; the trailing twelve-month figure through Mar 2026 stood at -$319.9 million (down 22.28% YoY), and the FY2026 full-year result was -$319.9 million, down 22.28% from the prior year.
• Operating Income eased to -$73.3 million in Q1 2026, from -$71.9 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$32.0 million in Q1 2022 to a low of -$90.4 million in Q2 2025.
• A 5-year average of -$60.3 million and a median of -$58.8 million in 2024 frame the typical range for Operating Income.
• Across the five-year window, Operating Income slumped 65.67% in 2023 and grew 7.7% in 2024, its largest moves.
• Tracing REPL's Operating Income over 5 years: stood at -$41.6 million in 2022, then slumped by 35.82% to -$56.5 million in 2023, then retreated by 16.77% to -$66.0 million in 2024, then dropped by 8.86% to -$71.9 million in 2025, then slipped by 2.05% to -$73.3 million in 2026.
• Business Quant data shows REPL's Operating Income at -$73.3 million in Q1 2026, -$71.9 million in Q4 2025, and -$84.3 million in Q3 2025.